Finance

Beta
Lists
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$9.55
-3.92%
(-0.39) 1D
$9.69
+1.47% (+0.14)
Pre-market
Closed: Jun 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCRX...
Open
$9.89
High
$10.04
Low
$9.48
Mkt. cap
2.43B
Avg. vol.
5.11M
Volume
1.12K
52-wk high
$10.94
52-wk low
$6.00
EPS
-$1.78
Beta
0.57
Shares outstanding
254.16M
No. of employees
435
Open
$9.89
High
$10.04
Low
$9.48
Mkt. cap
2.43B
Avg. vol.
5.11M
Volume
1.12K
52-wk high
$10.94
52-wk low
$6.00
EPS
-$1.78
Beta
0.57
Shares outstanding
254.16M
No. of employees
435
News stories
From sources across the web
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com
Analyst ratings
Based on 7 analysts giving stock ratings to BCRX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BCRX in the last 3 months.
Highest
Current $9.55
$32.00 (+235.08%)
Average
$23.33 (+144.29%)
Lowest
$13.00 (+36.13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Serge Belanger
Needham
Buy
Maintained
$16.00
+67.5%
06/29/2026
Laura Chico
Wedbush
Buy
Maintained
$21.00
+119.9%
05/07/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$28.00
+193.2%
05/07/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$32.00
+235.1%
05/07/2026
Stacy Ku
TD Cowen
Buy
Maintained
$30.00
+214.1%
05/06/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$13.00
+36.1%
05/06/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
04/16/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$17.00
+78%
02/18/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.14 / $0.11
+27.68%beat
Revenue / Est. (USD)
156.41M / 151.66M
+3.13%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
-
Operating expense
-
-
-
-
Total operating expenses
-
-
-
-
Operating income
-
-
-
-
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
-
EBT excluding unusual items
-
-
-
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-
-
-
-
Net profit margin
3.11%
8.09%
60.47%
-461.48%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer